Document Detail

Drug eluting stents versus PTA with GP IIb/IIIa blockade below the knee in patients with current ulcers--The BELOW Study.
MedLine Citation:
PMID:  20354490     Owner:  NLM     Status:  MEDLINE    
The study was designed as a feasibility trial to evaluate the use of GP IIb/IIIa blockade in connection with drug eluting stents, bare stents and PTA only. Sixty patients with current ulcers were randomly assigned to receive abciximab plus a sirolimus coated stent (N.=14), abciximab plus a bare stent (N.=16), abciximab plus PTA (N.=14) and PTA alone (N.=19). Angiographic control was performed at two and six months. Recanalization was successful in all cases. Two month restenosis rate was 9%, 45.5%, 67% and 46%. At six month follow-up restenosis rate was 9%, 67%, 75% and 58%, respectively; 14% of all patients had major amputations within six months. Adjunctive administration of abciximab during peripheral arterial intervention below the knee was found to be safe. Sirolimus coated stent administration was followed by a higher patency rate.
G Tepe; J Schmehl; S Heller; K Brechtel; M Heuschmid; M Fenchel; U Kramer; S Miller; C D Claussen
Publication Detail:
Type:  Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  The Journal of cardiovascular surgery     Volume:  51     ISSN:  0021-9509     ISO Abbreviation:  J Cardiovasc Surg (Torino)     Publication Date:  2010 Apr 
Date Detail:
Created Date:  2010-03-31     Completed Date:  2010-07-09     Revised Date:  2013-05-24    
Medline Journal Info:
Nlm Unique ID:  0066127     Medline TA:  J Cardiovasc Surg (Torino)     Country:  Italy    
Other Details:
Languages:  eng     Pagination:  203-12     Citation Subset:  IM    
Institute for Diagnostic and Interventional Radiology Hospital of Rosenheim, Rosenheim, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angioplasty, Balloon / adverse effects,  instrumentation*
Antibodies, Monoclonal / adverse effects,  therapeutic use*
Cardiovascular Agents / administration & dosage*
Drug-Eluting Stents*
Feasibility Studies
Immunoglobulin Fab Fragments / adverse effects,  therapeutic use*
Leg Ulcer / drug therapy,  physiopathology,  radiography,  therapy*
Limb Salvage
Lower Extremity / blood supply*
Platelet Aggregation Inhibitors / adverse effects,  therapeutic use*
Platelet Glycoprotein GPIIb-IIIa Complex / antagonists & inhibitors*
Prospective Studies
Prosthesis Design
Sirolimus / administration & dosage*
Time Factors
Treatment Outcome
Vascular Patency
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Cardiovascular Agents; 0/Immunoglobulin Fab Fragments; 0/Metals; 0/Platelet Aggregation Inhibitors; 0/Platelet Glycoprotein GPIIb-IIIa Complex; 53123-88-9/Sirolimus; X85G7936GV/abciximab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The use of the cryoplasty technique in the treatment of infrapopliteal lesions for Critical Limb Isc...
Next Document:  Developments in subintimal angioplasty in the infrainguinal segment.